ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
9 announcements with these filters
Aptus Pharma got BSE in-principle approval for a preferential issue of 15,99,270 shares at a minimum Rs. 280 each. The issue is worth about Rs. 44.78 Crore.
H1 FY27 revenue ₹48.92 Cr, EBITDA ₹7.68 Cr (15.7% margin), PAT ₹5.07 Cr; revenue exceeds full FY26 (₹46.57 Cr). Trading-heavy model with rising receivables and negative operating cash flow.
Aptus Pharma Ltd reported revenue from operations of ₹48.9 Cr (+239.6% YoY) and net profit of ₹5.1 Cr (+200.0% YoY) for H1 FY27.
Aptus Pharma Limited submitted the Regulation 74(5) compliance certificate for the quarter and half-year ended 30th September 2026, as received from its registrar.
Aptus Pharma Ltd issued a corrigendum to its 16th AGM notice regarding inadvertent errors in the explanatory statement for item no. 3.
Aptus Pharma Limited's Board has approved raising ₹44.88 Crore through a preferential equity issue. Funds will support manufacturing capacity expansion, working capital, and Pan-India growth initiatives.
Aptus Pharma has filed its Annual Report for FY 2025-26 with the exchange. The report includes the notice for the upcoming 16th Annual General Meeting.
Aptus Pharma Limited issued a notice for its 16th AGM on September 14, 2026, which includes a proposal for a preferential allotment of equity shares.
Aptus Pharma approved a preferential issue of 16,02,870 equity shares at Rs. 280 per share, raising approximately Rs. 44.88 Crore. The board also scheduled the 16th AGM.